Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
- 1 January 1998
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 351 (9096), 83-87
- https://doi.org/10.1016/s0140-6736(97)06088-1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centersJournal of Hepatology, 1997
- Short-term versus sustained response to interferon therapyDigestive Diseases and Sciences, 1996
- Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled studyJournal of Hepatology, 1996
- Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response ratesJournal of Hepatology, 1995
- Effect of Recombinant or Lymphoblastoid Interferon-α on Alanine Aminotransferase in Patients with Chronic Hepatitis C or Chronic Non-A Non-B HepatitisClinical Drug Investigation, 1995
- Serum Hepatitis C Virus RNA Levels in Chronic Hepatitis C-Importance for outcome of interferon alfa-2b treatmentScandinavian Journal of Infectious Diseases, 1994
- Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferonJournal of Hepatology, 1993
- Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis CJournal of Medical Virology, 1993
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989